SONOMA PHARMACEUTICALS INC (SNOA) Stock Price & Overview
NASDAQ:SNOA • US83558L3033
Current stock price
The current stock price of SNOA is 2.05 USD. Today SNOA is down by -8.89%. In the past month the price decreased by -12.82%. In the past year, price decreased by -51.77%.
SNOA Key Statistics
- Market Cap
- 3.546M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.04
- Dividend Yield
- N/A
SNOA Stock Performance
SNOA Stock Chart
SNOA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SNOA. When comparing the yearly performance of all stocks, SNOA is a bad performer in the overall market: 94.5% of all stocks are doing better.
SNOA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SNOA. SNOA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SNOA Earnings
SNOA Forecast & Estimates
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 636.39% is expected in the next year compared to the current price of 2.05.
For the next year, analysts expect an EPS growth of -96.42% and a revenue growth 11.38% for SNOA
SNOA Groups
Sector & Classification
SNOA Financial Highlights
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS increased by 48.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.74% | ||
| ROE | -98.19% | ||
| Debt/Equity | 0 |
SNOA Ownership
SNOA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.35 | 853.191B | ||
| JNJ | JOHNSON & JOHNSON | 17.82 | 544.731B | ||
| MRK | MERCK & CO. INC. | 22.17 | 278.01B | ||
| PFE | PFIZER INC | 8.97 | 155.349B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.29 | 121.259B | ||
| ZTS | ZOETIS INC | 16.62 | 49.697B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 28.547B | ||
| VTRS | VIATRIS INC | 5.82 | 17.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.35 | 11.291B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.359B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.199B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.101B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.82 | 4.797B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNOA
Company Profile
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Company Info
IPO: 2007-01-26
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 8
Phone: 18007599305
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What does SONOMA PHARMACEUTICALS INC do?
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
What is the stock price of SONOMA PHARMACEUTICALS INC today?
The current stock price of SNOA is 2.05 USD. The price decreased by -8.89% in the last trading session.
Does SNOA stock pay dividends?
SNOA does not pay a dividend.
What is the ChartMill rating of SONOMA PHARMACEUTICALS INC stock?
SNOA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy SNOA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SNOA.
What is the expected growth for SNOA stock?
The Revenue of SONOMA PHARMACEUTICALS INC (SNOA) is expected to grow by 11.38% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the short interest for SNOA stock?
The outstanding short interest for SONOMA PHARMACEUTICALS INC (SNOA) is 2.28% of its float.